ArticleActa neuropathologica communications2026
Effects of chemogenetic inhibition of serotonergic raphe-striatal neurons on L-DOPA-induced behaviors and neurochemistry in a rat model of Parkinson's disease.
Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The effects of chemogenetic targeting of serotonin-projecting pathways on L-DOPA-induced dyskinesia and psychosis in a bilateral rat model of Parkinson's disease.Frontiers in neural circuits · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Parkinson’s disease (PD) arises from the loss of nigrostriatal dopamine (DA) neurons in the substantia nigra pars compacta (SNc) precipitating motor impairments such as tremor, rigidity, and akinesia. DA replacement therapy via levodopa (L-DOPA), though effective, often results in the development of levodopa-induced-dyskinesia (LID), characterized by excessive hyperkinetic choreic and dystonic movements. While a myriad of mechanisms are implicated in LID, maladaptive neuroplasticity within raphe-striatal serotonin (5-HT) neurons appear to influence LID induction and severity. Although prior work has established a link between the 5-HT system and LID, tools utilized have been limited and the mechanism(s) remains elusive. Thus, the current set of experiments implemented a chemogenetic strategy by employing inhibitory DREADD (designer receptors exclusively activated by designer drugs) hM4Di expression specifically in 5-HT neurons of the DRN of hemi-parkinsonian TPH2-CRE transgenic rats, followed by chronic L-DOPA treatment. To assess the influence of DRN 5-HT inhibition on established LID, DREADD ligand C21 (0, 0.5, 3, 6 mg/kg, i.p.) was systemically administered in a within-subjects design in Experiment 1. In Experiment 2, we administered C21 (0, 0.1, 1.0 mM) directly into the DA-lesioned striatum via reverse in vivo microdialysis to determine if local DREADD-mediated 5-HT terminal inhibition per se, altered established LID. Results revealed C21 suppressed LID systemically (Experiment 1) and intrastriatally (Experiment 2) as well as reduced L-DOPA-induced striatal DA release. Post-mortem analyses revealed that nigrostriatal denervation alongside L-DOPA resulted in striatal reorganization of 5-HT innervation, highlighting a key component of raphe-striatal dysfunction in the expression of LID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.